anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a solid beverage with the throat clearing function and a preparation method thereof. The solid beverage is prepared from, by mass, 10-15% of boat-fruited sterculia seeds, 10-15% of syringa pubescens, 10-15% of honeysuckle, 5-8% of mint, 10-15% of liquorice, 5-10% of chrysanthemums, 5-10% of platycodon grandiflorum, 5-10% of siraitia grosvenorii, 5-8% of mulberries, 10-15% of radix ophiopogonis, 5-10% of figs and 5-10% of blueberries. The preparation method includes the following steps of material selection, frying, smashing, extraction, mixing, granulation, packaging and other procedures. The solid beverage is simple in preparation technology and convenient to store, carry and use. The made tea is golden in color, natural in fragrance, pure and good in taste. The beverage is made from pure natural resources which mainly are materials capable of being used as medicine and food at the same time, has the remarkable throat clearing effect, has no toxic and side effects on human bodies and is suitable for being used for a long time.
Trollioside A and its preparation method and application relate to an in vitro anti-inflammatory substance, and its preparation method and application. The invention provides a novel substance with in-vitro anti-inflammatory activity, and a preparation method and application thereof. Trollioside A has chemical name of 5- (2-hydroxylethyl) -2-methoxyphenyl-beta-D-glucopyranoside and molecular formula of C  15  H  22  O  8  . The method comprises the following steps: 1. extracting flos Trollii with 70% ethanol water solvent; 2. dispersing the ethanol recovered extract with water, and loading on D101 macroporous resin column; 3. separating and purifying the macroporous resin 30% ethanol eluate by repeated silica gel column chromatography, gel column chromatography and preparative high performance liquid chromatography to obtain a monomer compoundThe novel compound is identified by spectroscopy and named as trollflower glycoside A. Trollioside A is used for preparing anti-inflammatory medicine. IC of the present invention for inhibition of LPS-stimulated mouse macrophages (RAW 264.7) by Trollidine A of the present invention by proinflammatory factors TNF-alpha and IL-I beta  50  23.8 mu M and 16.3 mu M respectively, which shows that the anti-inflammatory agent has better anti-inflammatory activity in vitro. The invention belongs to the field of research on active ingredients of natural medicines.
Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
BACKGROUND: PRDM12 polyalanine tract expansions cause two different disorders: midfacial toddler excoriation syndrome (MiTES; itch with normal pain sensation associated with 18 homozygous alanines (18A); and congenital insensitivity to pain (CIP) with normal itch associated with 19 homozygous alanines (19A). Knowledge of the phenotype, genotype and disease mechanism of MiTES is incomplete. Why 18A vs. 19A PRDM12 can cause almost opposite phenotypes is unknown; no other polyalanine or polyglutamine tract expansion disease causes two such disparate phenotypes.
OBJECTIVES: To assess the genotype and phenotype of nine new, nine atypical and six previously reported patients diagnosed with MiTES.
METHODS: Using cell lines with homozygous PR domain zinc finger protein 12 (PRDM12) containing 12 alanines (12A; normal), 18A (MiTES) and 19A (CIP), we examined PRDM12 aggregation and subcellular localization by image-separation confocal microscopy and subcellular fractionation Western blotting.
RESULTS: MiTES presents in the first year of life; in all cases the condition regresses over the first decade, leaving scarring. The MiTES phenotype is highly distinctive. Features overlapping with PRDM12 CIP are rarely found. The genotype-phenotype study of the PRDM12 polyalanine tract shows that having 7-15 alanines is normal; 16-18 alanines is associated with MiTES; 19 alanines leads to CIP; and no clinically atypical cases of MiTES had a polyalanine tract expansion. PRDM12 aggregation and subcellular localization differed significantly between 18A and normal 12A cell lines and between 18A and 19A cell lines. MiTES is a new protein-aggregation disease.
CONCLUSIONS: We provide diagnostic criteria for MiTES and improved longitudinal data. MiTES and CIP are distinct phenotypes, despite their genotypes varying by a single alanine in the PRDM12 polyalanine tract. We found clear distinctions between the cellular phenotypes of normal, MiTES and CIP cells. We hypothesize that the developmental environment of the trigeminal ganglion is unique and critically sensitive to pre- and postnatal levels of PRDM12.
RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on a modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.
Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is an uncommon histiocytic disease with idiopathic etiology and unique pathology. Extra-nodal RDD that occurs in the nasal cavity is extremely unusual and the characteristic clinical features are unknown. Herein, we report a case of nasal septum RDD, with intermittent epistaxis from the left nasal cavity, which led to collapse of the nasal bridge. The patient underwent surgical biopsy, and a diagnosis of nasal septum RDD was established. No further treatment was performed. An enlarged mass was found in the second postoperative year which was treated by surgical excision in the third postoperative year. To improve the current diagnostic and therapeutic approach of extra-nodal RDD, we incorporate previous reports from the literature to discuss the pathological characteristics, pathogenesis, clinical manifestations, diagnosis, and therapy for this rare disease.
Improve visual skills through training and perceptual-cognitive learning could be a method aimed to repair partial neurophysiological deficits or produce new brain networks. Studies suggest that the mechanisms of attention and cortical plasticity have a role to play in information retrieval. In addition, he has been shown that Omega 3 in the form of phospholipids are the main component of nerve cells and taken orally makes a positive impact on behavior disorders such as depression or bipolar disorder. Their consumption would also help improve brain function while increasing the ability to concentrate.

The perceptual-cognitive ability is a very high level treatment of complex visual information. However, this ability only has our brain seems to be driven by the fact that the brain has great plasticity. This means that there is a neuronal reorganization in learning new capacity. 3D-MOT, or 3-Dimensional Multiple Object Tracking is a technique that allows the study of the visual system for tracking moving targets in 3D. It is a task of multifocal attentional pursuit which assesses the ability to keep the position of different moving targets from other similar objects. Performance is measured based on the number of objects that have been successfully followed. Previous studies have also shown that most young patients can typically take four objects simultaneously. In addition, this tracking capability, when speed is used as the dependent variable seems drivable. Therefore, Faubert and Sidebottom have shown that young people could significantly increase their speed thresholds. Legault and Faubert (2012) have demonstrated that training with the method of 3D-MOT generates significant improvements in visual-cognitive abilities as the perception of movement of the human body, a crucial index to avoid collisions when we navigate in a dense crowd for example.

The purpose of this project is to evaluate the impact of taking Omega-3 phospholipid form on perceptual-cognitive abilities, on the learning rate (curve) of young and older adults. The sample is composed of 40 young people (20 to 35) and 40 older adults (60-75) divided into two groups. The stimulus will be a task of multiple objects or 3D-MOT that consist to simultaneously track multiple moving objects among distractors, all will be presented on a 3D television screen . The performance of the observer (speed thresholds) will be evaluated based on three elements followed without error.
In a medical image recognition method, applied to a computer device, a to-be-recognized medical image set is obtained, where the to-be-recognized medical image set includes at least one to-be-recognized medical image. A to-be-recognized area corresponding to each to-be-recognized medical image in the to-be-recognized medical image set is extracted. The to-be-recognized area is a part of the to-be-recognized medical image. A recognition result of each to-be-recognized area through a medical image recognition model is determined. The medical image recognition model is obtained through training according to a medical image sample set. The medical image sample set includes at least one medical image sample, and each medical image sample carries corresponding annotation information. The annotation information is used for representing a type of the medical image sample, and the recognition result is used for representing the a of the to-be-recognized medical image.
A device comprising an extracellular matrix having an internal pH between 4.0 and 6.0 is discussed. This matrix contains heparin or a heparin-related compound such as heparan sulfate. Preferably the matrix also contains fibronectin or a fragment thereof. The matrix will bind to a protein having a pH dependent binding to heparin such as VEGF, preferably VEGF 121 or VEGF 165. The device will release the protein as the pH increases to physiological pH, such as 7.0 to 7.5. The device can be used to deliver a drug to a specific site. For example, with VEGF to a site in need of angiogenesis.
Teratogenic Effects. Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin should not be used during pregnancy unless the potential benefit justifies the potential risk to both fetus and mother (see WARNINGS). An expert review of published data on experiences with ciprofloxacin use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (quantity and quality of data=fair), but the data are insufficient to state that there is no risk.9

A controlled prospective observational study followed 200 women exposed to fluoroquinolones (52.5% exposed to ciprofloxacin and 68% first trimester exposures) during gestation.10 In utero exposure to fluoroquinolones during embryogenesis was not associated with increased risk of major malformations. The reported rates of major congenital malformations were 2.2% for the fluoroquinolone group and 2.6% for the control group (background incidence of major malformations is 1 to 5%). Rates of spontaneous abortions, prematurity and low birth weight did not differ between the groups and there were no clinically significant musculoskeletal dysfunctions up to one year of age in the ciprofloxacin exposed children. 

Another prospective follow-up study reported on 549 pregnancies with fluoroquinolone exposure (93% first trimester exposures).11 There were 70 ciprofloxacin exposures, all within the first trimester. The malformation rates among live-born babies exposed to ciprofloxacin and to fluoroquinolones overall were both within background incidence ranges. No specific patterns of congenital abnormalities were found. The study did not reveal any clear adverse reactions due to in utero exposure to ciprofloxacin. 

No differences in the rates of prematurity, spontaneous abortions, or birth weight were seen in women exposed to ciprofloxacin during pregnancy.9,10 However, these small postmarketing epidemiology studies, of which most experience is from short term, first trimester exposure, are insufficient to evaluate the risk for less common defects or to permit reliable and definitive conclusions regarding the safety of ciprofloxacin in pregnant women and their developing fetuses. Reproduction studies have been performed in rats and mice using oral doses up to 100 mg/kg (0.6 and 0.3 times the maximum daily human dose based upon body surface area, respectively) and have revealed no evidence of harm to the fetus due to ciprofloxacin. In rabbits, oral ciprofloxacin dose levels of 30 and 100 mg/kg (approximately 0.4- and 1.3-times the highest recommended therapeutic dose based upon mg/m2) produced gastrointestinal toxicity resulting in maternal weight loss and an increased incidence of abortion, but no teratogenicity was observed at either dose level. After intravenous administration of doses up to 20 mg/kg (approximately 0.3-times the highest recommended therapeutic dose based upon mg/m2) no maternal toxicity was produced and no embryotoxicity or teratogenicity was observed. (See WARNINGS.)
PURPOSE:To obtain a medicine extremely inhibiting formation of metastatic focus of cancerous cell and having extremely slight cytotoxicity, comprising 6-O-triphenyl-D-glyco-delta-lactam as an active ingredient. CONSTITUTION:This cancerous cell metastasis inhibitor comprises 6-O- triphenylmethyl-D-glyco-delta-lactam as an active ingredient. The inhibitor is made into an oral or parenteral preparation and is administered intravenouslv, via artery or skin, subcutaneously, intracutaneously, rectally, intramuscularly or orally. Strong effect is shown by administering the inhibitor directly to a tumor. A daily dose is 100-3,000mg and administered once to several times dividedly. Carcinostatic effect can be raised by use in surgical operation therapy or radiation therapy even by simultaneous administration with an existing carcinostatic agent.
BACKGROUND: This study aims to review the clinical characteristics, therapeutic response and outcome of idiopathic pulmonary hemosiderosis (IPH), and discover the risk factors for recurrence in children with IPH, which will be helpful for the early diagnosis and reasonable treatment of this disease.
METHODS: Children with a diagnosis of IPH were enrolled in the study. Clinical data of the children were collected and analysed.
RESULTS: A total of 32 patients with regular follow-up after diagnosis were included in this study. Anaemia, cough and haemoptysis constituted the most common initial symptoms of the disease, and the incidences were 90.6%, 75% and 56.2%, respectively. The mean gap between the onset of symptoms and diagnosis was 5 (0.25-36) months. Most of the children experienced remission (complete and partial remission) over the course of 6 months of treatment, but 19 of the children experienced relapse. The causes of disease recurrence included respiratory tract infection (37.5%), corticosteroid (CS) reduction (18.8%), and irregular medication (6.3%). Interestingly, we found that children with history of allergy (HR 4.255, 1.107-16.356) tended to experience disease recurrence (p = 0.01).
CONCLUSIONS: Cough and anaemia are the most common symptoms in children with IPH. The recurrence rate of this disease is high, and respiratory tract infection is the most common cause of its recurrence. High-dose CS impluse therapy cannot reduce the recurrence rate of the disease. Allergic history was an import factor associated with disease recurrence.
TRIAL REGISTRATION: This study is a retrospective and observational study, which does not involve human specimens or clinical intervention. Therefore, clinical trial registration is not required, and there is no clinical trial number. However, the study was approved by the Institutional Review Board/Ethics Committee affiliated with West China Second University Hospital, Sichuan University (Ethics review number 2022074).
Sterile alpha and TIR motif containing 1 (SARM1) is an inducible NADase that localizes to mitochondria throughout neurons and senses metabolic changes that occur after injury. Minimal proteomic changes are observed upon either SARM1 depletion or activation, suggesting that SARM1 does not exert broad effects on neuronal protein homeostasis. However, whether SARM1 activation occurs throughout the neuron in response to injury and cell stress remains largely unknown. Using a semiautomated imaging pipeline and a custom-built deep learning scoring algorithm, we studied degeneration in both mixed-sex mouse primary cortical neurons and male human-induced pluripotent stem cell-derived cortical neurons in response to a number of different stressors. We show that SARM1 activation is differentially restricted to specific neuronal compartments depending on the stressor. Cortical neurons undergo SARM1-dependent axon degeneration after mechanical transection, and SARM1 activation is limited to the axonal compartment distal to the injury site. However, global SARM1 activation following vacor treatment causes both cell body and axon degeneration. Context-specific stressors, such as microtubule dysfunction and mitochondrial stress, induce axonal SARM1 activation leading to SARM1-dependent axon degeneration and SARM1-independent cell body death. Our data reveal that compartment-specific SARM1-mediated death signaling is dependent on the type of injury and cellular stressor.
1481480 Electrolytic treatment of cells in suspension KERNFORSCHUNGSANLAGE JULICH GmbH 14 Jan 1975 [2 Feb 1974] 1616/75 Heading C7B The permeability of the membrane of cells of organisms e.g. of bacteria or erythrocytes is increased by subjecting a physiological, electrolyte solution containing the cells in suspension, e.g. cattle blood cells in buffer solution containing NaCI, KCl, MgCl 2 , CaCl 2 , tris(hydroxymethyl) aminomethane and adenosine triphosphate, to an electrical field, preferably by passing the solution from inlet nozzle 8 to outlet discharge pipe 9 in container 1 subdivided into chambers 4; 5 by a non-conducting, e.g. glass, wall 2, the solution passing through an aperture 3 in the wall surrounding the focus of a focused electrical field provided by an electrode 6 in each chamber. Each chamber may have an inlet 7 for supply of electrolyte solution separate from the inlet nozzle 8 for the electrolyte solution containing the cells. The solution containing the cells may be extracted from chamber 5 through outlet pipe 9 by suction. Alternatively, Fig. 2, the apparatus may have three non-conducting containers 10, 11, 12, arranged concentrically to form an outer, intermediate and inner chamber, with concentric electrodes 13, 14 arranged in the outer and intermediate chambers. The solution containing the cells is passed via nozzle 15 in the outer chamber through passage 16 surrounding the focus of the elctrical field then through aperture 17 into the inner container 12 by suction via connector 18; losses of solution incurred are compensated for via connections 19, 20, air being removed via connector 21. The inner container may be provided with a thermocouple 22. The cells or organisms so treated may be used for synthesis and degradation of substances dissolved in an aqueous solution containing at least 0À5 mM of Mg and/or Ca with K ions.
Globally, non-communicable diseases (NCDs) are the leading cause of death and disability with a particularly high burden in Low- and middle-income countries (LMICs), where more than 75% of all premature NCD deaths occur. Lesotho is a typical example of an African LMIC where NCDs are overtaking Human immunodeficiency virus (HIV)/AIDS and other infectious diseases as major cause of disability, morbidity and early death. HIV and NCDs are chronic diseases and share several characteristics such as the asymptomatic initial phase, progression to complications with disability and early death, and need for life-long treatment. The Ministry of Health (MoH) of Lesotho has therefore proposed in its NCD strategic plan that lessons learnt from the HIV program should be taken up to similarly reduce the existing access barriers to NCD care. Two scoping reviews have shown that the evidence on how and to what extent task shifting to lay workers can successfully be implemented for NCDs in sub-Sahara Africa is very limited. This open, prospective cohort study aims at generating evidence on community-based screening, diagnosis and management of uncomplicated arterial hypertension (aHT), Diabetes mellitus (DM) and other chronic diseases by lay Village health worker (VHWs) in a rural sub-Saharan African setting. It is to establish an observational cohort (ComBaCaL cohort) with regular monitoring of chronic disease indicators and risk factors in Butha-Buthe and Mokhothlong districts in Lesotho that will be managed by lay Chronic Care Village Health Workers (CC-VHWs), supported by a dedicated tablet-based eHealth application. The prevalence of common chronic diseases and associated risk factors in the cohort population and will be assessed and their development over time will be monitored. Initial focus will be on aHT, DM, cardiovascular disease risk factors (CVDRFs) and HIV. Other conditions may be included at a later stage. The effect of the ComBaCaL activities on condition- specific care cascade outcomes, such as screening coverage, disease awareness, linkage to care, engagement in care and disease control rates will be analyzed. Cohort variables will be assessed at baseline and pre-specified analyses to assess the effect of the ComBaCaL on chronic disease care cascades will be conducted at six months (range 150-240 days) and twelve months (range 300-480 days) after enrolment. Variables which may change over time will be reassessed during follow-up visits at intervals of around six months.

The ComBaCaL cohort will be a platform for nested pragmatic trials (Trials within a Cohort, TwiCs) assessing chronic disease care interventions.